CARsgen-B (02171) Rises Nearly 6% on Inclusion of Solid Tumor Cell Therapy Project in National Major Scientific Project

Stock News01-05

CARsgen-B (02171) rose nearly 6%, and as of the time of writing, the stock was up 5.94% to HKD 16.23, with a turnover of HKD 18.8074 million. On December 30, the company announced through its official WeChat account that the "Key Technologies and Innovative Drug R&D for Immunocellular Therapy of Solid Tumors" project, led by its subsidiary Shanghai CARsgen Therapeutics Co., Ltd., has been officially approved and included in the 2025 project list of the National Major Scientific and Technological Project for Innovative Drug Research and Development. The National Major Scientific and Technological Project represents the highest-level research and development initiative in China's strategic frontier sectors, designed to achieve independent breakthroughs in key core technologies and their industrial application. This specific project, under the direction of "Novel Drug R&D for Immunocellular Therapy of Solid Tumors," will systematically advance the fundamental innovation and technological攻关 of next-generation immunocyte therapies, targeting the clinical and scientific bottlenecks currently present in solid tumor treatment. The project will concentrate on cutting-edge areas of solid tumor immunocyte therapy, striving to develop breakthrough therapeutic technologies and innovative products, thereby accelerating the clinical translation of related drugs and the establishment of an engineering preparation system.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132935236?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 11:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132935236","market":"us","top_or_hot":-1,"title":"CARsgen-B (02171) Rises Nearly 6% on Inclusion of Solid Tumor Cell Therapy Project in National Major Scientific Project","media":"Stock News","content":"<p>CARsgen-B (02171) rose nearly 6%, and as of the time of writing, the stock was up 5.94% to HKD 16.23, with a turnover of HKD 18.8074 million.\nOn December 30, the company announced through its official WeChat account that the \"Key Technologies and Innovative Drug R&D for Immunocellular Therapy of Solid Tumors\" project, led by its subsidiary Shanghai CARsgen Therapeutics Co., Ltd., has been officially approved and included in the 2025 project list of the National Major Scientific and Technological Project for Innovative Drug Research and Development.\nThe National Major Scientific and Technological Project represents the highest-level research and development initiative in China's strategic frontier sectors, designed to achieve independent breakthroughs in key core technologies and their industrial application.\nThis specific project, under the direction of \"Novel Drug R&D for Immunocellular Therapy of Solid Tumors,\" will systematically advance the fundamental innovation and technological攻关 of next-generation immunocyte therapies, targeting the clinical and scientific bottlenecks currently present in solid tumor treatment.\nThe project will concentrate on cutting-edge areas of solid tumor immunocyte therapy, striving to develop breakthrough therapeutic technologies and innovative products, thereby accelerating the clinical translation of related drugs and the establishment of an engineering preparation system.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARsgen-B (02171) Rises Nearly 6% on Inclusion of Solid Tumor Cell Therapy Project in National Major Scientific Project</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARsgen-B (02171) Rises Nearly 6% on Inclusion of Solid Tumor Cell Therapy Project in National Major Scientific Project\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-05 11:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CARsgen-B (02171) rose nearly 6%, and as of the time of writing, the stock was up 5.94% to HKD 16.23, with a turnover of HKD 18.8074 million.\nOn December 30, the company announced through its official WeChat account that the \"Key Technologies and Innovative Drug R&D for Immunocellular Therapy of Solid Tumors\" project, led by its subsidiary Shanghai CARsgen Therapeutics Co., Ltd., has been officially approved and included in the 2025 project list of the National Major Scientific and Technological Project for Innovative Drug Research and Development.\nThe National Major Scientific and Technological Project represents the highest-level research and development initiative in China's strategic frontier sectors, designed to achieve independent breakthroughs in key core technologies and their industrial application.\nThis specific project, under the direction of \"Novel Drug R&D for Immunocellular Therapy of Solid Tumors,\" will systematically advance the fundamental innovation and technological攻关 of next-generation immunocyte therapies, targeting the clinical and scientific bottlenecks currently present in solid tumor treatment.\nThe project will concentrate on cutting-edge areas of solid tumor immunocyte therapy, striving to develop breakthrough therapeutic technologies and innovative products, thereby accelerating the clinical translation of related drugs and the establishment of an engineering preparation system.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1132935236","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132935236","pubTimestamp":1767583558,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CARsgen-B (02171) rose nearly 6%, and as of the time of writing, the stock was up 5.94% to HKD 16.23, with a turnover of HKD 18.8074 million. On December 30, the company announced through its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股","02171":"科济药业-B","BK1585":"昨日强势股"},"translate_title":"实体瘤细胞治疗项目纳入国家大科学工程，科济健-B(02171)涨近6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"CARsgen-B (02171) rose nearly 6%, and as of the time of writing, the stock was up 5.94% to HKD 16.23, with a turnover of HKD 18.8074 million.\nOn December 30, the company announced through its official WeChat account that the \"Key Technologies and Innovative Drug R&D for Immunocellular Therapy of Solid Tumors\" project, led by its subsidiary Shanghai CARsgen Therapeutics Co., Ltd., has been officially approved and included in the 2025 project list of the National Major Scientific and Technological Project for Innovative Drug Research and Development.\nThe National Major Scientific and Technological Project represents the highest-level research and development initiative in China's strategic frontier sectors, designed to achieve independent breakthroughs in key core technologies and their industrial application.\nThis specific project, under the direction of \"Novel Drug R&D for Immunocellular Therapy of Solid Tumors,\" will systematically advance the fundamental innovation and technological攻关 of next-generation immunocyte therapies, targeting the clinical and scientific bottlenecks currently present in solid tumor treatment.\nThe project will concentrate on cutting-edge areas of solid tumor immunocyte therapy, striving to develop breakthrough therapeutic technologies and innovative products, thereby accelerating the clinical translation of related drugs and the establishment of an engineering preparation system.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132935236","isCrawlerRequest":true}